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Statins cholesterol lowering and mental health: a review
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Background
Epidemiological and clinical studies have suggested that
powerful cholesterol lowering may have adverse effects on
mood and psychological well-being. Reports in the early
1990s showed that LDL cholesterol lowering might have
an undesirable impact on mental health (possible
increase of violence, accidents and suicide). As a result,
the scientific interest is strongly focused on the effects of
statins therapy on mental status (i.e. irritability, depres-
sive symptoms, and anxiety). The aim of our study is to
review the literature involving statins and mental health
and to analyze it by time.
Materials and methods
Three medical libraries (MEDLINE, COCHRANE, ISI Web
of Science) were systematically searched in order to inves-
tigate the cumulative randomized evidence on the possi-
ble existence of correlation between statin treatment and
mental health. Three chronological periods were further
defined for by-time analysis of medical literature: early
1990s, late 1990s and 2000s reports. We identified forty-
five peer reviewed related reports and only seven related
randomized studies.
Results
In the early 1990s a meta-analysis raised concerns about a
possible increase of deaths in groups receiving treatment
for lowering serum cholesterol levels. This resulted in fur-
ther investigation of the association between the reduc-
tion of cholesterol concentration and deaths or violent
tendencies. In the late 1990s several double-blind rand-
omized trials showed that there is no statistically signifi-
cant effect of low cholesterol concentrations on the
psychological well-being. At present, a strong hypothesis
has been put forward about the effect of the statins them-
selves on some specific psychological parameters. This
effect seems to be unrelated to cholesterol levels. Many
randomized controlled studies came to the conclusion
that there is a reduction of depressive symptoms, anxiety
and hostility in patients treated with statins. The
lipophilic statins, as opposed to all other cholesterol-low-
ering drugs, appeared primarily responsible for the
observed effect on psychological well-being. A choles-
terol-independent immunomodulatory mechanism has
been postulated. Penetration of the blood-brain-barrier
by the lipophilic molecule results in: inhibition of HMG-
CoA reductase, suppression of the Th1-type cytokines,
interferon-gamma (IFN-γ) and interleukins IL-2 and IL-
12; promotion of the secretion of Th-2-type cytokines and
IL-4 and IL-5 and IL-10; lowering of tryptophan availabil-
ity and decreasing of serotonine levels. Whether statins
improve tryptophan metabolism is worth being tested in
more clinical trials.
Discussion
At present, statins are supposed to improve the psycholog-
ical well-being and to reduce depressive symptoms,
despite the early 1990s observations that statin treatment
might be a risk factor for self-destructive behaviour even
suicide. Individuals with current statin use may have a
lower risk of developing depression, an effect that could
be also explained by improved quality of life due to the
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decreased risk of cardiovascular events or higher health
consciousness in patients receiving long-term treatment.
It seems to be possible that an independent immunoreg-
ulatory statin effect is responsible for the alteration of the
psychological well-being in treated patients. Further labo-
ratory and clinical research, additional to meta-analysis of
the existed randomised trials would be useful.
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